SCHEMBL2349796

SCHEMBL2349796

COC(=O)C(O)c1cccc(NC(=O)OC(C)(C)C)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.46
HDAC3 O15379 1/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC2 Q92769 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
CYP17A1 P05093 1/20 0.44
PRMT5 O14744 1/20 0.43
WDR77 Q9BQA1 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
KAT6A Q92794 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA9 Q16790 1/20 0.41
NAMPT P43490 1/20 0.41
BACE1 P56817 2/20 0.41
SYK P43405 1/20 0.40
PPARG P37231 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25810625 0.86 PTGS1 (0.50) IDO1HDAC3HDAC1HDAC2HDAC8
SCHEMBL19426702 0.86 IDO1 (0.49) IDO1HDAC3HDAC1HDAC2HDAC8
SCHEMBL25908182 0.85 IDO1 (0.47) IDO1HDAC3HDAC1HDAC2HDAC8
SCHEMBL28032815 0.85 MEN1 (0.63) IDO1HDAC3HDAC1HDAC2HDAC8
SCHEMBL21377414 0.85 MEN1 (0.63) IDO1HDAC3HDAC1HDAC2HDAC8
SCHEMBL13734965 0.85 MEN1 (0.63) IDO1HDAC3HDAC1HDAC2HDAC8
SCHEMBL2353309 0.84 IDO1 (0.36) IDO1HDAC3HDAC1HDAC2HDAC8
SCHEMBL2353305 0.84 IDO1 (0.36) IDO1HDAC3HDAC1HDAC2HDAC8
SCHEMBL12743181 0.83 FADS1 (0.51) IDO1HDAC3HDAC1HDAC2HDAC8
SCHEMBL26016215 0.83 CYP17A1 (0.46) CYP17A1CA12CA1CA9NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110319366-A1 Plasma Carboxypeptidase B Inhibitors BUCKMAN BRAD (US) 2011-12-29 US disclosed
US-8008325-B2 Plasma carboxypeptidase B inhibitors BAYER SCHERING PHARMA AG (DE) 2011-08-30 US disclosed
EP-2204373-A1 Phosphonic acid as Plasma Carboxypeptidase B Inhibitors Bayer Schering Pharma Aktiengesellschaft (DE) 2010-07-07 EP disclosed
US-7528173-B2 Plasma carboxypeptidase B inhibitors SCHERING AKTIENGESELLSHAFT (DE) 2009-05-05 US disclosed
US-20090093520-A1 PLASMA CARBOXYPEPTIDASE B INHIBITORS BUCKMAN BRAD 2009-04-09 US disclosed
US-20060247213-A1 Plasma carboxypeptidase b inhibitors SCHERING AKTIENGESELLSCHAFT (DE) 2006-11-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319366-A1 Plasma Carboxypeptidase B Inhibitors CPB1, CPB2, CPA1 IDO1 1366/4885HDAC3 1132/4885HDAC1 1831/4885
US-20090093520-A1 PLASMA CARBOXYPEPTIDASE B INHIBITORS CPB1, CPB2, CPA1 IDO1 1366/4885HDAC3 1132/4885HDAC1 1831/4885
US-20060247213-A1 Plasma carboxypeptidase b inhibitors CPB1, CPB2, CPA1 IDO1 1359/4885HDAC3 1245/4885HDAC1 1682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.